The Capital Markets team advised the underwriters in the completion of Metsera’s initial public offering of 15,277,778 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds from the offering were approximately $275.0 million, before deducting underwriting discounts and commissions and offering expenses. Metsera’s common stock began trading on the Nasdaq under the ticker symbol “MTSR” on January 31, 2025.
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has raised over $500 million in financing from leading healthcare investors and is based in New York City.
The Goodwin team was led by Rachael Bushey, Bill Collins, Adam V. Johnson, Kristen McCarthy and Austin Church and included Duncan A. Greenhalgh, Miho Kaneko, Lily Xu, Susan Lee, Sukrti Thonse, Matt Wetzel, Dustin Schaefer, Erini R. Svokos, Katerina Stavrianidis, Sarah Bock, Jacqueline Klosek, Isabelle Staff, Dan Karelitz and Maggie Wong with invaluable assistance from Marishka DeToy.
For more information on the deal, please read the press release.